Investigational Drug Information for APD791
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for APD791?
APD791 is an investigational drug.
There have been 5 clinical trials for APD791.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2021.
The most common disease conditions in clinical trials are Acute Coronary Syndrome, Raynaud Disease, and Neoplasm Metastasis. The leading clinical trial sponsors are Arena Pharmaceuticals, Asan Medical Center, and IlDong Pharmaceutical Co Ltd.
There are thirteen US patents protecting this investigational drug and one hundred and twenty-nine international patents.
Summary for APD791
| US Patents | 13 |
| International Patents | 129 |
| US Patent Applications | 36 |
| WIPO Patent Applications | 15 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 1 (2021-08-01) |
| Vendors | 29 |
Recent Clinical Trials for APD791
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis | Arena Pharmaceuticals | Phase 2 |
| Dose-escalation, Repeated and Single Oral Dosing Study | Asan Medical Center | Phase 1 |
| Dose-escalation, Repeated and Single Oral Dosing Study | IlDong Pharmaceutical Co Ltd | Phase 1 |
Clinical Trial Summary for APD791
Top disease conditions for APD791
Top clinical trial sponsors for APD791
US Patents for APD791
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| APD791 | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| APD791 | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| APD791 | See Plans and Pricing | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| APD791 | See Plans and Pricing | Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition | NITTO DENKO CORPORATION (Osaka, JP) | See Plans and Pricing |
| APD791 | See Plans and Pricing | Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition | NOTTO DENKO CORPORATION (Osaka, JP) | See Plans and Pricing |
| APD791 | See Plans and Pricing | 3-phenyl-pyrazole derivatives as modulators of the 5-HT.sub.2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (San Diego, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for APD791
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| APD791 | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
| APD791 | Canada | CA3023278 | 2036-05-05 | See Plans and Pricing |
| APD791 | China | CN107847398 | 2036-05-05 | See Plans and Pricing |
| APD791 | European Patent Office | EP3452003 | 2036-05-05 | See Plans and Pricing |
| APD791 | European Patent Office | EP3981392 | 2036-05-05 | See Plans and Pricing |
| APD791 | Hong Kong | HK1249728 | 2036-05-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
